UPDATED: Bluebird CFO resigns as company faces bleak economic future
For bluebird bio, the FDA’s verdict on its gene therapies — slated for August and September, respectively — could be a life-or-death decision.
The biotech, once a high-flying Wall Street darling that represented a new, flashy breed of drug developers, revealed to investors in a quarterly filing that its cash problems “raise substantial doubt regarding its ability to continue as a going concern” in the coming year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.